



VERITY
P H A R M A C E U T I C A L S

Verity Pharmaceuticals Inc. is a privately held Canadian Corporation

Verity Pharmaceuticals:

Canadian specialty Pharma focused on high demand medical products that are relevant Rx Products and are currently in short supply or absent from the market.

A low risk stable business model focused on high profit products

Our Unfair Advantage

Identified market holes for necessary & relevant Rx's.



Private Company with low overhead – focused on generating significant profits where Big Pharma fails.

Corporate Details

- Federally Registered Canadian Health Science Company:
 - British Columbia incorporated June, 2016
- Privately held company, comprised of 4 founding common share holders from the medical and pharma corp. community;
 - Seed round investors:
 - Capital Canada Investment bank engaged.
- Proven experienced pharma executive management
- Globally recognized Scientific Advisory Board
- Focused on high profit, in demand legacy products

Leadership Team



Howard Glase
Chief Executive Officer

- International pharmaceutical experience with \$1.3 billion portfolio;
- Proven scientific business entrepreneur .
- 25+ years of pharmaceutical experience



Dr. Neil Fleshner
Chief Medical Officer
Chair: Advisory Board

- Leading Uro-Oncologist
- Global Expert;
- Highly Published;
- Chairman, Dept. of Urology, University of Toronto
- Proven Entrepreneur.



Robert Rieder
Chairman

- Co-Founder/ previous CEO Essa Pharma Inc.;
- led Cardiome from pre-clinical to approval in EU;
- extensive public company experience (raised \$250 million).



Mr. Paul Dunne
CFO

- Fellow of the Institute of Chartered Accountants in Ireland
- 30 year multi national corporate experience
- Experienced CA working with medium to large business



Advisory Board



Dr. J. Barkin
Advisor

- Clinical Professor of Surgery, Univ. of Toronto
- Urologist Executive Editor-in-Chief: Canadian Journal of Urology;
- Global KOL



Dr. S. Herschorn
Advisor

- Professor Urology, University of Toronto
- Past-President, Canadian Urological Association
- Global KOL.



Dr. R. Devenyi
Advisor

- Ophthalmologist-in-Chief and Director of Retinal Services at the University Health Network, Toronto
- Global KOL



Dr. D. Dunne
Advisor

- Professor and Director, University of Victoria MBA Program
- Consultant to numerous multi national Pharma



TRACTION:

We are in final stages of a definitive agreement with:

- an EU, French based company with two Ophthalmology products and a diagnostic imaging surgery agent.
- An EU, German based company with two Bladder Cancer agents. (Reviewing 6 other agents)
- An American company with an Urology Agent
- An EU, German Company, with a Infectious Disease agent.

We are speaking/meeting with 4 other Pharma's and their portfolio of products.